The second drug selected is pyrimethamine (5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine), an antiparasitic drug used as an antimalarial for its ability to inhibit dihydrofolate reductase [38], or together with a sulfonamide to treat toxoplasmosis [39]. Here, DHFR is linked to toxoplasmosis.